

Munich Cancer Registry



- Incidence and Mortality
- Selection Matrix
- Homepage
- *Deutsch*

ICD-10 C00-C97: All cancers (excl. C44)

Survival

Year of diagnosis	1988-1997	1998-2014
Patients	62,529	312,947
Diseases	65,943	343,595
Cases evaluated	58,333	254,009
Creation date	03/02/2016	
Export date	12/23/2015	
Population	4.64 m	



Munich Cancer Registry at Munich Cancer Center
Marchioninstr. 15
Munich, 81377
Germany

<http://www.tumorregister-muenchen.de/en>

<http://www.tumorregister-muenchen.de/en/facts/surv/sC0097E-ICD-10-C00-C97-All-cancers-excl.-C44-survival.pdf>




Figure 1a. Relative survival of patients with all cancers (excl. C44) by year of diagnosis. Included in the evaluation are 251,492 cases diagnosed between 1998 and 2014.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2011, and are represented by gray diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Years	Year of diagnosis													
	1998		1999		2000		2001		2002		2003		2004	
	n=9,482		n=9,401		n=9,166		n=9,491		n=15,594		n=15,688		n=15,956	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	77.6	80.0	78.6	80.9	80.6	82.9	80.5	82.7	80.9	83.2	80.3	82.5	80.7	82.8
2	68.7	72.7	69.7	73.6	71.9	75.8	71.4	75.2	71.7	75.6	71.5	75.4	71.8	75.5
3	63.2	68.5	63.9	69.2	66.1	71.4	65.9	71.1	66.1	71.5	66.2	71.4	66.2	71.3
4	59.3	66.0	59.8	66.3	62.0	68.7	61.9	68.3	62.2	68.9	62.2	68.7	62.3	68.6
5	55.9	63.7	56.3	64.1	58.2	66.0	58.3	65.8	59.0	66.9	58.9	66.7	59.1	66.7
6	53.1	62.0	53.4	62.2	55.4	64.3	55.5	64.1	55.7	64.8	56.1	65.1	56.3	65.0
7	50.2	60.1	50.9	60.6	52.8	62.9	53.0	62.7	52.9	63.1	53.3	63.4	53.5	63.2
8	47.8	58.7	48.6	59.2	50.5	61.5	50.8	61.4	50.6	61.9	50.9	62.1	51.1	61.9
9	45.4	57.1	46.4	57.9	48.4	60.5	48.6	60.3	48.2	60.4	48.7	60.9	48.8	60.6
10	43.1	55.6	44.4	56.8	46.2	59.2	46.7	59.3	46.0	59.3	46.2	59.4	46.8	59.5
11	41.0	54.2	42.4	55.6	44.3	58.2	44.7	58.2	44.0	58.3	44.1	58.3	45.0	58.8
12	39.5	53.5	40.7	54.7	42.4	57.1	42.9	57.3	42.1	57.3				
13	37.7	52.4	38.7	53.4	40.6	56.2	40.8	56.0	40.3	56.4				
14	35.9	51.3	37.2	52.7	38.7	54.9								
15	34.2	50.2	35.8	52.1										

<i>cont'd</i>	Year of diagnosis													
	2005		2006		2007		2008		2009		2010		2011	
	n=15,837		n=16,036		n=18,528		n=18,667		n=18,264		n=17,812		n=17,860	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	80.0	82.2	79.7	81.8	80.5	82.6	80.6	82.7	80.4	82.4	80.1	82.2	79.9	82.0
2	71.4	75.1	70.7	74.3	72.4	76.0	72.1	75.7	71.4	74.9	71.6	75.0	71.1	74.6
3	65.8	70.8	65.1	70.0	66.8	71.8	66.7	71.5	66.1	70.9	66.2	71.0	65.8	70.6
4	61.5	67.8	61.2	67.4	62.6	68.8	62.8	69.0	62.1	68.2	62.5	68.6		
5	58.3	65.8	58.1	65.5	59.4	66.8	59.6	66.9	59.2	66.4	59.9	67.2		
6	55.2	63.7	55.1	63.7	56.4	65.0	57.1	65.6	56.7	65.2				
7	52.7	62.4	52.3	62.0	53.8	63.5	55.1	64.8						
8	50.3	61.1	49.7	60.4	51.7	62.5								
9	48.0	59.7												

<i>cont'd</i>	Year of diagnosis					
	2012		2013		2014	
	n=17,793		n=16,229		n=9,688	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	80.0	82.1	80.1	82.1	85.7	87.8
2	71.7	75.2	72.5	76.0		
3	66.8	71.7				

Table 1b. Observed (obs.) and relative (rel.) survival of patients with all cancers (excl. C44) by year of diagnosis for period 1998-2014 (N=251,492).




Figure 2a. Survival of patients with all cancers (excl. C44) by gender. Included in the evaluation are 251,492 cases diagnosed between 1998 and 2014.

Years	Gender			
	Male n=128,433		Female n=123,059	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	78.3	80.6	82.4	84.3
2	68.9	73.0	74.3	77.5
3	63.3	68.9	69.1	73.3
4	59.2	66.4	65.2	70.5
5	55.9	64.5	62.1	68.4
6	52.9	62.9	59.3	66.5
7	50.2	61.6	56.7	64.8
8	47.6	60.3	54.5	63.4
9	45.2	59.1	52.3	62.1
10	42.9	58.1	50.3	60.8

Table 2b. Observed (obs.) and relative (rel.) survival of patients with all cancers (excl. C44) by gender for period 1998-2014 (N=251,492).




Figure 2c. Conditional relative 2 / 5-year survival of patients with all cancers (excl. C44) by gender. For 251,492 of 251,492 cases diagnosed between 1998 and 2014 valid data could be obtained for this item.

Years	Gender					
	Male			Female		
	n	Cond. surv. % 2 yrs	5 yrs	n	Cond. surv. % 2 yrs	5 yrs
0	128,433	73.0	64.5	123,059	77.5	68.4
1	95,064	85.7	78.4	95,272	87.2	79.2
2	78,036	91.2	85.0	79,605	91.4	84.2
3	65,574	94.1	88.5	67,647	93.7	87.4
4	55,839	95.5	90.5	57,897	94.9	89.2
5	47,581	96.3	91.8	49,241	95.5	90.5
6	40,198	96.8	92.8	41,344	96.3	91.6
7	33,246	97.2	93.9	34,075	96.9	92.8
8	26,803	97.7	94.7	27,937	97.1	92.9
9	21,796	98.0	95.3	22,910	97.5	93.7
10	17,377	98.7	96.8	18,474	98.0	94.0

Table 2d. Conditional relative 2 / 5-year survival of patients with all cancers (excl. C44) by gender for period 1998-2014 (N=251,492).

Conditional relative survival rates refer to the relative survival probability, in this case for 2 and 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100%) under the condition of being alive for a certain time period (x-axis in Figure 2a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup gender="Male", who are alive at least 3 years after cancer diagnosis, the conditional relative 2-year survival rate is 94.1% (n=65,574).




Figure 3a. Observed survival of patients with all cancers (excl. C44) by age category. Included in the evaluation are 251,492 cases diagnosed between 1998 and 2014.




Figure 3b. Relative survival of patients with all cancers (excl. C44) by age category. Included in the evaluation are 251,492 cases diagnosed between 1998 and 2014.

Years	Age category													
	0-29 yrs n=5,181		30-39 yrs n=9,486		40-49 yrs n=22,668		50-59 yrs n=43,883		60-69 yrs n=73,354		70-79 yrs n=64,918		80-89 yrs n=28,499	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.8	95.8	95.4	95.5	90.8	91.0	85.8	86.2	83.1	84.2	76.1	78.6	62.3	68.2
2	92.2	92.3	91.3	91.4	84.7	85.0	77.5	78.4	75.0	77.1	66.4	71.1	49.9	60.2
3	89.9	90.0	88.4	88.6	80.6	81.1	72.9	74.2	70.1	73.1	60.2	67.0	41.4	55.6
4	88.6	88.7	86.7	87.0	78.1	78.8	69.8	71.5	66.5	70.5	55.5	64.4	35.0	52.7
5	87.5	87.7	85.3	85.7	76.1	77.0	67.3	69.5	63.7	68.7	51.3	62.4	29.6	50.7
6	86.8	87.0	83.9	84.3	74.4	75.5	65.3	67.9	61.1	67.2	47.6	61.0	24.7	48.7
7	85.8	86.0	82.6	83.2	72.9	74.2	63.4	66.5	58.8	66.0	43.9	59.6	20.4	46.8
8	85.0	85.3	81.6	82.2	71.7	73.3	61.9	65.5	56.8	65.1	40.3	58.2	16.8	45.4
9	84.5	84.8	80.7	81.5	70.5	72.3	60.2	64.4	54.8	64.4	36.8	56.9	13.7	44.1
10	84.2	84.5	79.9	80.8	69.6	71.6	58.7	63.5	52.8	63.6	33.4	55.9	10.9	42.8

Years	Age category <i>cont'd</i> 90+ yrs n=3,503	
	obs. %	rel. %
	obs. %	rel. %
0	100.0	100.0
1	46.6	58.8
2	31.7	51.2
3	22.4	47.4
4	16.4	45.5
5	11.3	43.0

Table 3c. Observed (obs.) and relative (rel.) survival of patients with all cancers (excl. C44) by age category for period 1998-2014 (N=251,492).




Figure 4a. Relative survival of patients with all cancers (excl. C44) by morphology. For 300,815 of 309,709 cases diagnosed between 1988 and 2014 valid data could be obtained for this item.

Morphology														
Years	Epithelial npl., NOS n=12,362		Squamous cell npl. n=25,786		Adenocarcinomas n=134,419		Cystic, mucin. a. serous npl. n=12,190		Ductal and lobular neoplasms n=48,718		Melanomas n=15,439		Hodgkin a. non-Hodgkin l. n=10,113	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	45.6	46.9	70.4	72.0	81.8	84.4	72.9	75.1	94.1	95.6	96.0	97.8	82.4	84.4
2	29.5	31.1	55.9	58.3	73.7	78.3	59.0	62.4	88.8	91.7	91.9	95.3	76.1	79.3
3	24.4	26.4	48.6	51.7	68.1	74.6	50.7	55.0	84.2	88.3	88.3	93.3	72.4	76.8
4	21.7	24.1	44.2	47.9	63.9	72.1	45.0	50.1	80.1	85.4	85.4	91.8	68.8	74.4
5	19.8	22.6	40.8	45.1	60.5	70.3	41.1	47.0	76.6	82.9	83.0	90.8	65.6	72.1
6	18.6	21.8	38.0	42.8	57.3	68.8	37.9	44.6	73.4	80.7	80.5	89.6	62.5	70.0
7	17.4	20.8	35.4	40.7	54.4	67.4	35.1	42.5	70.3	78.5	78.2	88.6	59.9	68.1
8	16.5	20.3	33.1	38.8	51.6	66.1	32.9	41.0	67.6	76.8	76.1	87.8	57.4	66.4
9	15.3	19.3	31.1	37.1	49.1	65.1	31.0	39.8	65.1	75.1	74.3	87.1	55.1	64.7
10	14.6	18.8	29.4	35.7	46.7	64.0	29.3	38.6	62.5	73.4	72.4	86.4	53.4	63.6

Morphology				
Years	Mult. morphology n=8,748		NOS n=33,040	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	81.2	83.1	77.0	78.9
2	71.9	75.2	65.8	68.9
3	65.6	70.1	59.6	63.6
4	61.9	67.4	55.3	60.1
5	58.6	65.2	51.8	57.4
6	55.9	63.4	48.8	55.1
7	53.3	61.7	46.4	53.3
8	51.1	60.4	44.2	51.6
9	49.1	59.2	42.2	50.1
10	47.4	58.3	40.4	48.8

Table 4b. Observed (obs.) and relative (rel.) survival of patients with all cancers (excl. C44) by morphology for period 1988-2014 (N=300,815).




Figure 4c. Relative survival of patients with all cancers (excl. C44) by morphology. For 246,387 of 251,492 cases diagnosed between 1998 and 2014 valid data could be obtained for this item.

Morphology														
Years	Epithelial npl., NOS n=9,933		Squamous cell npl. n=19,792		Adenocarcinomas n=111,511		Cystic, mucin. a. serous npl. n=9,622		Ductal and lobular neoplasms n=40,822		Melanomas n=12,478		Hodgkin a. non-Hodgkin l. n=8,288	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	43.2	44.5	69.7	71.2	81.4	84.0	73.1	75.3	93.6	95.2	95.8	97.6	81.9	83.9
2	27.1	28.6	55.7	58.1	73.7	78.1	59.4	62.8	88.3	91.3	91.7	95.1	75.7	79.0
3	22.0	23.8	48.4	51.4	68.3	74.5	50.8	55.1	84.0	88.1	88.0	92.9	72.3	76.8
4	19.2	21.3	44.2	47.9	64.3	72.2	44.9	50.1	80.3	85.6	85.2	91.5	68.7	74.4
5	17.2	19.7	41.0	45.3	61.0	70.6	40.9	46.8	77.1	83.4	82.8	90.5	65.8	72.5
6	16.1	18.9	38.4	43.3	57.9	69.1	37.5	44.2	74.1	81.6	80.4	89.5	62.8	70.5
7	14.7	17.7	35.9	41.2	55.1	67.9	34.7	42.1	71.2	79.6	78.1	88.5	60.2	68.7
8	13.7	17.0	33.6	39.3	52.5	66.8	32.7	40.8	68.6	78.0	76.1	87.6	58.2	67.5
9	12.4	15.8	31.6	37.7	50.0	65.8	30.7	39.5	66.1	76.4	74.3	87.0	56.1	66.1
10	11.7	15.2	30.0	36.4	47.6	64.8	29.0	38.4	63.5	74.6	72.4	86.3	54.1	64.9

Morphology				
Years	Mult. morphology n=7,145		NOS n=26,796	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	80.4	82.3	76.4	78.3
2	70.7	73.9	65.1	68.1
3	64.4	68.7	58.8	62.8
4	60.8	66.1	54.5	59.3
5	57.6	63.9	51.0	56.6
6	55.1	62.3	48.1	54.3
7	52.5	60.5	45.8	52.5
8	50.6	59.6	43.6	50.9
9	48.6	58.5	41.7	49.5
10	47.0	57.7	40.0	48.3

Table 4d. Observed (obs.) and relative (rel.) survival of patients with all cancers (excl. C44) by morphology for period 1998-2014 (N=246,387).




Figure 5a. Time to first progression of 212,974 patients with all cancers (excl. C44) diagnosed between 1998 and 2014 (M0 only in solid cancers) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

Years	Type of progression						
	Any type (CI)	Any type (1-KM)	Local relapse (CI)	Local relapse (1-KM)	Lymph node (CI)	Lymph node (1-KM)	Distant metastasis (CI)
	n=212,974 %	n=212,974 %	n=212,974 %	n=212,974 %	n=212,974 %	n=212,974 %	n=212,974 %
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1	15.3	15.7	2.1	2.4	0.6	0.7	5.7
2	22.4	23.2	4.0	4.6	1.1	1.3	9.7
3	26.2	27.3	5.0	6.0	1.4	1.7	12.0
4	28.5	29.9	5.7	6.9	1.6	2.0	13.5
5	30.2	31.9	6.2	7.6	1.8	2.2	14.6
6	31.6	33.5	6.6	8.2	1.9	2.4	15.4
7	32.6	34.7	6.9	8.7	2.0	2.6	16.1
8	33.4	35.8	7.2	9.2	2.1	2.7	16.7
9	34.2	36.9	7.5	9.7	2.2	2.9	17.2
10	34.9	37.8	7.7	10.1	2.2	3.0	17.6
11	35.3	38.4	7.9	10.4	2.3	3.1	17.9
12	35.8	39.1	8.0	10.7	2.3	3.2	18.2
13	36.2	39.7	8.2	11.1	2.4	3.3	18.5
14	36.5	40.3	8.3	11.4	2.4	3.4	18.7
15	36.8	40.7	8.5	11.7	2.5	3.5	18.8

<i>cont'd</i>	Type of progression		
	Distant metast. (1- KM)	NOS (CI)	NOS (1-KM)
	n=212,974	n=212,974	n=212,974
Years	%	%	%
0	0.0	0.0	0.0
1	6.2	2.6	2.8
2	10.7	3.9	4.5
3	13.5	4.5	5.4
4	15.4	5.0	6.1
5	16.9	5.3	6.6
6	18.0	5.6	7.0
7	18.9	5.8	7.3
8	19.7	5.9	7.5
9	20.5	6.0	7.7
10	21.2	6.1	7.9
11	21.7	6.2	8.0
12	22.2	6.2	8.1
13	22.7	6.2	8.2
14	23.1	6.3	8.3
15	23.4	6.3	8.3

Table 5b. Time to first progression of patients with all cancers (excl. C44) for period 1998-2014 (N=212,974).




Figure 5c. Observed post-progression survival of 75,301 patients with all cancers (excl. C44) diagnosed between 1998 and 2014. These 75,301 patients with documented progression events during their course of disease represent 30.1 % of the totally 249,979 evaluated cases (incl. M1, n=37,005, 14.8 %). Patients with cancer relapse documented via death certificates only were excluded (n=26,395, 10.6 %). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “Any type” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potentially considered in more than one subgroup.

Years	Type of progression				
	Any type n=75,301 %	Local relapse n=14,897 %	Lymph node n=4,456 %	Distant metastasis n=56,181 %	NOS n=11,249 %
0	100.0	100.0	100.0	100.0	100.0
1	52.1	63.1	64.1	45.5	60.4
2	35.9	47.2	47.7	28.1	47.8
3	27.7	39.2	38.6	19.7	41.2
4	23.0	33.7	32.3	15.1	37.2
5	20.0	30.5	28.8	12.2	33.9
6	17.7	27.4	25.5	10.4	30.9
7	16.0	25.0	23.4	9.1	28.4
8	14.7	23.2	22.4	8.1	26.5
9	13.7	21.8	21.6	7.5	24.8
10	12.7	20.4	20.4	6.9	22.7

Table 5d. Observed post-progression survival of patients with all cancers (excl. C44) for period 1998-2014 (N=75,301).




Figure 5e. Observed post-progression (any type) survival of 95,585 patients with all cancers (excl. C44) diagnosed between 1988 and 2014 by period of progression.

Years	Period of progression		
	1988-1997 n=14,947	1998-2006 n=35,116	2007+ n=45,522
	%	%	%
0	100.0	100.0	100.0
1	52.2	52.8	54.3
2	35.0	36.6	38.4
3	26.4	28.4	30.2
4	21.3	23.7	25.3
5	18.4	20.6	22.0
6	16.2	18.2	19.5
7	14.6	16.4	18.0
8	13.3	14.9	17.0
9	12.2	13.8	
10	11.1	12.8	

Table 5f. Observed post-progression (any type) survival of patients with all cancers (excl. C44) for period 1988-2014 by period of progression (N=95,585).

Shortcuts

MCR Munich Cancer Registry, Germany

NCI National Cancer Institute, USA

SEER Surveillance, Epidemiology, and End Results, USA

UICC Union for International Cancer Control, Geneva

DCO Death certificate only Death certificate provides the only notification to the registry.

NA Not available

NOS Not otherwise specified

OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate)

Date of entry: diagnosis
Event: death from any cause

RS Relative survival Survival compared to “general population”, ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival

AS Assembled survival Assembled chart of observed, expected, relative survival

CS Conditional survival Survival probability under the condition of surviving a given period of time

TTP Time to progression Time to first progression / relapse
Date of entry: diagnosis
Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression

1-KM 1 minus Kaplan-Meier estimator
 (“inverse” Kaplan-Meier estimator)

CI Cumulative incidence
Death as competing risk (according to Kalbfleisch und Prentice)

PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate)
Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression
Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C00-C97: All cancers (excl. C44) [Internet]. 2016 [updated 2016 Mar 2; cited 2016 May 1]. Available from: <http://www.tumorregister-muenchen.de/en/facts/surv/sC0097E-ICD-10-C00-C97-All-cancers-excl.-C44-survival.pdf>

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables

Fig./Tbl.	Page
1a Relative survival by year of diagnosis (chart)	2
1b Survival by year of diagnosis (table)	2
2a Survival by gender (chart)	4
2b Survival by gender (table)	4
2c Conditional survival by gender (chart)	5
2d Conditional survival by gender (table)	5
3a Observed survival by age category (chart)	6
3b Relative survival by age category (chart)	6
3c Survival by age category (table)	7
4a Relative survival by morphology 1988+ (chart)	8
4b Survival by morphology 1988+ (table)	8
4c Relative survival by morphology 1998+ (chart)	9
4d Survival by morphology 1998+ (table)	9
5a Time to first progression (chart)	10
5b Time to first progression (table)	10
5c Observed post-progression survival (chart)	12
5d Observed post-progression survival (table)	12
5e Observed post-progression survival by period of progression (chart)	13
5f Observed post-progression survival by period of progression (table)	13